secwatch.observer — SEC 8-K summary ====================================== Issuer: SELLAS Life Sciences Group, Inc. (SLS) CIK: 0001390478 Form: 8-K Filed at: 2026-11-17T12:14:19+00:00 Accession: 0001104659-26-128825 Event type: other_material Sentiment: positive Materiality: 0.90 Item codes: 7.01, 8.01, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 SELLAS GPS hits Phase 3 REGAL primary endpoint: median OS 24.0 vs 14.7 months, HR 0.59 (p=0.035) -------------------------------------------------------------------------------- - Median overall survival 24.0 months for galinpepimut-S (GPS) vs 14.7 months for best available treatment; 41% reduction in risk of death (HR 0.59, two-sided p=0.035). - REGAL enrolled AML patients in second or later complete remission (CR2/CRp2+) after second-line or later salvage therapy who were ineligible for allogeneic stem cell transplant. - Topline analysis conducted at the pre-specified 80 death events per the trial's statistical analysis plan; treatment arms balanced on prognostic factors. - GPS generally well tolerated; treatment-related adverse events mostly grade 1/2 local injection site reactions, no new safety signals. - SELLAS plans an FDA meeting on an accelerated filing strategy and to advance BLA preparation for GPS in the first half of 2027; secondary endpoints pending. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465926128825/0001104659-26-128825-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1390478/000110465926128825/tm2629947d1_8k.htm HTML page: https://secwatch.observer/filing/0001104659-26-128825 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer